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bactericidal activity
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Abstract
Bacteriophage endolysins (lysins) bind to a cell wall substrate and cleave peptidoglycan, resulting in hypotonic lysis
of the phage-infected bacteria. When purified lysins are added externally to Gram-positive bacteria they mediate
rapid death by the same mechanism. For this reason, novel therapeutic strategies have been developed using such
enzybiotics. However, like other proteins introduced into mammalian organisms, they are quickly cleared from
systemic circulation. PEGylation has been used successfully to increase the in vivo half-life of many biological
molecules and was therefore applied to Cpl-1, a lysin specific for S. pneumoniae. Cysteine-specific PEGylation with
either PEG 10K or 40K was achieved on Cpl-1 mutants, each containing an additional cysteine residue at different
locations To the best of our knowledge, this is the first report of the PEGylation of bacteriophage lysin. Compared
to the native enzyme, none of the PEGylated conjugates retained significant in vitro anti-pneumococcal lytic
activity that would have justified further in vivo studies. Since the anti-microbial activity of the mutant enzymes
used in this study was not affected by the introduction of the cysteine residue, our results implied that the
presence of the PEG molecule was responsible for the inhibition. As most endolysins exhibit a similar modular
structure, we believe that our work emphasizes the inability to improve the in vivo half-life of this class of
enzybiotics using a cysteine-specific PEGylation strategy.
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Introduction
Streptococcus pneumoniae is the first cause of otitis
media and a common cause of sinusitis, community-
acquired pneumonia, bacteremia, and meningitis (Jacobs,
2004,). Antibiotic misuse and overuse has progressively
selected for resistance against major drug classes, and
treatment failures are widely reported (Fuller and Low,
2005,; Klugman, 2002,). This justifies the search for new
drugs with different mechanisms of action. The bacter-
iolytic action of bacteriophage lysins enables the release
of phage progeny from the bacterial sacculus. Purified
pneumococcal phage lysin Cpl-1 has been used to suc-
cessfully treat pneumococcal sepsis, endocarditis, menin-
gitis, and pneumonia in rodent models (Entenza et al.,
2005,; Grandgirard et al., 2008,; Loeffler et al., 2003,).
However, due to its short circulating half-life (~20.5
minutes) (Loeffler et al., 2003,), optimal efficacy requires
repeated injections or continuous infusion (Entenza et
al., 2005,). We recently showed that pre-dimerization of
Cpl-1, which doubles the molecular weight of the
enzyme, decreased its plasma clearance by a factor of
ten (Resch et al., 2011,). PEGylation (Veronese and
Pasut, 2005,) was shown to extend even more so the
serum half-life of interferon-a2b from minutes to hours
(Ramon et al., 2005,) and of lysostaphin from 1 to 24 h
(Walsh et al., 2003,). Here we mono-PEGylated (Gaberc-
Porekar et al., 2008,; Walsh et al., 2003) Cpl-1 at various
cysteine residues and determined the anti-pneumococcal
activity of the resulting conjugates.
Materials and methods
Reagents
Plasmid mini-prep kits were bought from Qiagen
(Valencia, CA, USA). The QuickChange II Site-Directed
Mutagenesis Kit was purchased from Stratagene (Cedar
Creek, TX, USA). Mutagenic primers were obtained
from Fischer Biotechnology (Pittsburgh, PA, USA) and
DNA sequencing reactions were performed by Genewiz
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(South Plain, NJ, USA). DEAE-Sepharose, HiLoad 16/60
SuperdexTM 200 prep grade column, and PD-10 desalt-
ing columns were obtained from GE Healthcare Bio-
Sciences Corp. (Piscataway, NJ, USA). Amicon Ultra
centrifugal units Ultracel 30K were from Millipore (Car-
rigtwohill, Co. Cork, Ireland). Chemically competent
Escherichia coli (E. coli) Max Efficiency DH5a cells and
NuPAGE 4-12% Bis-Tris Gels were from Invitrogen
(Carlsbad, CA, USA). Poly-ethylene glycol maleimide
MW 10 kDa (PEG 10) and Y-shape poly-ethylene glycol
maleimide MW 40 kDa (PEG 40) were purchased from
Jenkem Technology (Allen, TX, USA). All other chemi-
cals were from Sigma-Aldrich (Saint Louis, MO. USA).
Choosing PEGylation sites
In the present study, seven mutants previously described
elsewhere as showing comparable antimicrobial activity
to parent Cpl-1 were included (Resch et al., 2011). The
mutants are as follows: Cpl-1C45S;Q85C Cpl-1C45S;D194C
Cpl-1C45S;N214C Cpl-1C45S;G216C Cpl-1C45S;D256C Cpl-
1C45S;S269C Cpl-1C45S;D324C (Table 1). A previous study
on lysostaphin PEGylation suggesting that future studies
should focus on mono-PEGylation in order to prevent
total inhibition of enzyme activity (Walsh et al., 2003),
led us to choose to neo-introduce a single exposed
cysteine in our Cpl-1 mutants. The nucleotide sequence
of Cpl-1 can be access from the Genbank database with
accession number NC_001825.
Construction of plasmids carrying mutated Cpl-1 genes
Plasmids carrying the genes encoding for the Cpl-1
mutants included in this study were constructed as
described elsewhere (Resch et al., 2011). Briefly, the
plasmid encoding Cpl-1C45S was constructed using the
QuickChange II Site-Directed Mutagenesis Kit with
appropriate primers (Table 1) in order to introduce the
desired mutation in the Cpl-1 gene originally carried on
the pJML6 plasmid (Loeffler et al., 2003), following the
manufacturer instructions. The plasmids encoding the
mutant Cpl-1 proteins were further generated by the
same approach (Table 1 for the list of primers) using
the plasmid carrying the Cpl-1C45S gene as template.
Plasmids containing the mutated genes were further
transformed in E. coli DH5a following the manufacturer
protocol. The presence of the mutations was confirmed
by DNA sequencing.
Production and purification of Cpl-1 mutants
The production and purification of all proteins followed
a protocol that has already been described for Cpl-1
(Loeffler and Fischetti, 2003,) and Cpl-1 mutants (Resch
et al., 2011). Briefly, E. coli DH5a cells were grown in
Luria-Broth (LB) for 16 h aerobically at 37°C with agita-
tion at 250 rpm. The cultures were diluted 10X (vol/vol)
and allowed to grow for an additional 5 h in the same
conditions. Protein expression was induced by the addi-
tion of 2% (w/v) lactose to the cultures. 16 h later, cells
were pelleted, resuspended in phosphate buffer 50 mM,
pH 7.4 (enzyme buffer), and sonicated on ice (three
cycles of 30 sec at 70% power, Sonoplus, Bandelin Elec-
tronics, Berlin, Germany). Cell debris was pelleted by
centrifugation (1 h at 4°C and 15,000 rpm) and superna-
tants were treated with 20 units (20 U) of DNAse I for
16 h at 4°C. 0.45 μm filtered supernatants were applied
to a DEAE-Sepharose fast flow column previously equi-
librated with enzyme buffer. Following a wash step with
enzyme buffer containing 1 M NaCl, the enzymes were
eluted with enzyme buffer containing 10% (w/v) choline.
Table1 List of mutagenic primers used in site-directed mutagenesis experiments
Cpl-1
mutant
Forward mutagenic primer Reverse mutagenic primer
Cpl-1C45S 5’-CGA CCT ATT TAA ACC CTA GCT TGT CTG CTC AAG TGG AGC
AGT CAA ACC C-3’
5’-GGG TTT GAC TGC TCC ACT TGA GCA GAC AAG CTA GGG TTT
AAA TAG GTC G-3’
Cpl1C45S;
Q85C
5’-GTT TTT CCT TGA CAA CGT GCC TAT GTGCGT TAA ATA CCT TGT
ATT GGA CTA CG-3’
5’-CGT AGT CCA ATA CAA GGT ATT TAA CGCACA TAG GCA CGT
TGT CAA GGA AAA AC-3’
Cpl1C45S;
D194C
5’-GTT AGA CGA TGA AGA AGA CTG CAA GCC AAA GAC CGC TGG
A-3’
5’-TCC AGC GGT CTT TGG CTT GCA GTC TTC TTC ATC GTC TAA C-
3’
Cpl1C45S;
N214C
5’-GGG TGG TGG TTC AGA CGA TGC AAT GGC AGT TTC CCT TA-3’ 5’-TAA GGG AAA CTG CCA TTG CAT CGT CTG AAC CAC CAC CC-3’
Cpl-1C45S;
G216C
5’-GTG GTG GTT CAG ACG AAA CAA TTG CAG TTT CCC TT-3’ 5’-AAG GGA AAC TGCAAT TGT TTC GTC TGA ACC ACC AC-3’
Cpl-1C45S;
D256C
5’-AAA TGG TAC TAC CTC AAG TGC AAC GGC GCA ATG GCG AC-3’ 5’-GTC GCC ATT GCG CCG TTG CAC TTG AGG TAG TAC CAT TT-3’
Cpl-1C45S;
S269C
5’-GTT GGG TGC TAG TCG GGT GCG AGT GGT ATT ATA TGG AC-3’ 5’-GTC CAT ATA ATA CCA CTC GCA CCC GAC TAG CAC CCA AC-3’
Cpl-1C45S;
D324C
5’-ACA CAA ACG GAG AGC TTG CATGCA ATC CAA GTT TCA CGA
AAG-3’
5’-CTT TCG TGA AAC TTG GAT TGCATG CAA GCT CTC CGT TTG
TGT-3’
Mutated positions are underlined.
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After extensive dialysis (cutoff 30,000 kDa) against
enzyme buffer, the purified enzymes were concentrated
using Ultracel 30K centrifugal filters and stored at -20°
C.
PEGylation of Cpl-1 mutants
Purified mutant enzymes were reduced for 30 min at
room temperature (RT) in enzyme buffer containing 10
mM dithiotreitol (DTT), and desalted on PD-10 col-
umns previously equilibrated with enzyme buffer. Pro-
tein concentrations were adjusted to 1 mg/ml and either
PEG maleimide MW 10,000 kDa (PEG 10K) or Y-
shaped PEG Maleimide MW 40,000 kDa (PEG 40K) was
added (1/25 and 1/10 mol protein/mol PEG for PEG
10K and 40K, respectively). After a 15 min. incubation
period at RT with constant gentle agitation, the excess
of unbound PEG was removed by applying the mixtures
to a DEAE-Sepharose column previously equilibrated
with enzyme buffer. PEGylated conjugates and residual
fractions of non-PEGylated enzymes were eluted with
enzyme buffer containing 10% (w/v) choline, and then
purified by gel filtration on a HiLoad 16/60 Superdex™
200 prep grade column pre-equilibrated in enzyme buf-
fer. Fractions containing the purified PEGylated enzymes
were pooled, concentrated using Ultracel 30K centrifu-
gal filters and stored at -20°C until further use.
In vitro killing assay
The killing assay was performed using S. pneumoniae
strain DCC1490 (serotype 14) obtained from A. Tomasz
and has been described elsewhere (Loeffler and Fischetti,
2003,; Loeffler et al., 2001). Briefly, DCC1490 was grown
to log-phase in aerobic conditions without agitation
(OD595 nm of 0.3) in brain heart infusion (BHI) at 37°C.
After centrifugation and re-suspension of DCC1490 in
enzyme buffer at a concentration of 109 cfu/ml, serial
dilutions of enzymes were added to the cells. Reaction
kinetics were obtained by measuring the decrease of the
OD595 nm at 37°C over a period of 28 min. in a EL808
microplates reader (Biotek Instruments Gmbh, Luzern,
Switzerland).
Results
As previously reported (Resch et al., 2011), Cpl-1C45S;
D194C generated the expected 37 kDa band plus a 74
kDa band on non-reducing SDS-PAGE (Figure 1, lane
2). The 74 kDa band vanished upon reduction with 10
mM DTT (Figure 1, lane 3) and therefore corresponded
to a dimer. Indeed, dimerization was likely due to
cysteine cross-bridging, thus indirectly indicating that
the de novo introduced cysteines were properly exposed.
A similar migration pattern was observed with all
mutants in this study (data not shown). The seven fully
active mutants (Resch et al., 2011) were further
PEGylated. Figure 1 depicts a representative PEGylation
experiment with PEG 40K. As determined by ImageJ
(Abramoff et al., 2004), a small fraction of enzyme (3-
12%, depending on the mutant), was not PEGylated
(Figure 1, lane 5 for Cpl-1C45S;D194C). After gel filtration,
fractions containing highly pure PEGylated conjugates
were recovered (Figure 1, lane 9 and 10 for Cpl-1C45S;
D194C) and pooled. The seven PEGylated conjugates lost
100% of their activity in the in vitro killing assay (data
not shown), suggesting that the bulky effect of the PEG
40K molecule drastically interfered with enzyme
function.
We reasoned that smaller adducts would be less detri-
mental to the enzyme, and therefore repeated the
experiments with PEG 10K. Figure 2 depicts a represen-
tative PEGylation experiment with PEG 10K. This
PEGylation reaction was also incomplete with 15-20% of
residual non-PEGylated enzyme remaining in the mix-
ture (Figure 2, lane 2 for Cpl-1C45S;D194C). Following gel
filtration, fractions containing highly pure PEG 10K con-
jugates (Figure 2, lane 6, 7 and 8 for Cpl-1C45S;D194C)
were separated from fractions containing non-PEGylated
enzymes (Figure 2, lane 11 and 12 for Cpl-1C45S;D194C)
and pooled. As for PEG 40K conjugates, none of the
PEG 10K conjugates retained significant in vitro anti-
microbial activity when tested in the in vitro killing
assay (data not shown). The reduced electrophoretic
migration of the PEG conjugates (ca.120 kDa instead of
Figure 1 Non-reducing SDS-PAGE of Cpl-1C45S;D194C PEGylated
with PEG 40K. Protein ladder (lanes 1 and 6); non-reduced Cpl-
1C45S;D194C (lane 2); Cpl-1C45S;D194C reduced with 10 mM DTT before
and after desalting on a PD-10 column (lane 3 and 4, respectively);
Cpl-1C45S;D194C PEGylated with PEG 40K and purified on a DEAE-
sepharose column (lane 5); further purification of Cpl-1C45S;D194C
PEGylated with PEG 40K on a Hiload 16/60 Superdex column (lane 7
to 11). Fractions 9 and 10 were pooled and further used in the in
vitro killing assay.
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77 kDa and ca. 60 kDa instead of 47 kDa for PEG 40K
and PEG 10K conjugates; Figure 1, lane 5 and Figure 2,
lane 2, respectively) might be attributed to steric hin-
drance of the PEG molecule.
Discussion
While introducing cysteines at several sites on Cpl-1 did
not alter its bactericidal activity, PEGylation on these
residues totally abrogated it. This might be related to
the complex structure and mode of action of the
enzyme, which makes it susceptible to bulky adducts.
Cpl-1 has a C-terminal domain that mediates binding to
choline in the cell wall for adequate positioning of the
N-terminal catalytic domain to cleave its substrate (Diaz
et al., 1990,; Perez-Dorado et al., 2007,). Optimal posi-
tioning may also depend on enzyme C-terminus dimeri-
zation, as described for the pneumococcal autolysin
LytA (Romero et al., 2007).
Susceptibility to PEG-related hindrance is supported
by the fact that PEGylation on the hinge region (C194)
inhibited activity, in spite of the fact that this region is
independent of both the binding and active domains.
Adding a bulky adduct to this location is thought to
affect flexibility of the hinge and interfere with optimal
orientation of the enzyme into the wall.
The present results do not preclude that PEGylation at
other sites or with different types of PEG could possibly
extend Cpl-1 half-life with less detrimental effect on its
bactericidal activity. However, we believe that this work
highlights the fact that cysteine-specific PEGylation
could be unsuitable for a large set of enzybiotics with a
similar architecture.
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